Karyopharm nearly doubles on Phase I MM data for selinexor

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) jumped $22.77 (94%) to $47.12 on Friday after reporting preliminary data from eight multiple myeloma patients in a Phase I trial of the company's selinexor (...